US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neuraxis, Inc.

2.29

-0.0100-0.43%

Post-market: 2.24-0.0500-2.18%19:34 EDT

Volume:90.17K

Turnover:205.74K

Market Cap:20.05M

PE:-1.85

High:2.34

Open:2.28

Low:2.26

Close:2.30

Loading ...

Overview Company News Filings

NeurAxis Stock Doubles with FDA Clearance for IB-Stim

Nasdaq Falls 100 Points; Home Depot Sales Top Views

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

MT Newswires Live

NeurAxis Receives FDA Clearance on IB-Stim for Treating Pediatric Dyspepsia; Shares Rise Sharply Pre-Bell

MT Newswires Live

BRIEF-Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach

Neuraxis Awarded First Ever FDA Clearance for the Treatment of Pediatric Fap/Functional Dyspepsia (FD) and Associated Nausea Symptoms

THOMSON REUTERS

Neuraxis Inc - Commercial Rollout for New Indication Begins Immediately

THOMSON REUTERS

Neuraxis Inc: Clearance Covers Patients Aged 8-21

THOMSON REUTERS

NeurAxis, Inc. Reports Increased Sales Amidst Losses

CORRECTION: Neuraxis Q1 EPS $(0.33) Down From $(0.32) YoY, Sales $895.65K Up From $646.63K YoY

Neuraxis Q1 EPS $(0.33) Misses $(0.24) Estimate, Sales $895.65K Miss $725.00M Estimate

Press Release: NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth

NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges

NeurAxis, Inc. Reports Strong Q4 2024 Results

Neuraxis reports Q4 revenue $761,000 vs. $531,000 last year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NRXS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NRXS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NRXS\",,,,,undefined,":{"symbol":"NRXS","market":"US","secType":"STK","nameCN":"Neuraxis, Inc.","latestPrice":2.29,"timestamp":1749844800000,"preClose":2.3,"halted":0,"volume":90168,"hourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.29,"latestTime":"19:34 EDT","volume":5108,"amount":11451.48,"timestamp":1749857675670},"delay":0,"floatShares":4721001,"shares":8754300,"eps":-1.234667,"marketStatus":"Market Closed","change":-0.01,"latestTime":"06-13 16:00:00 EDT","open":2.28,"high":2.3385,"low":2.26,"amount":205735.7124576,"amplitude":0.03413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.234667,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1691553600000,"exchange":"AMEX","adjPreClose":2.3,"preHourTrading":{"tag":"盘前","latestPrice":2.2799,"preClose":2.3,"latestTime":"08:43 EDT","volume":4424,"amount":9928.376192,"timestamp":1749818619389},"postHourTrading":{"tag":"盘后","latestPrice":2.24,"preClose":2.29,"latestTime":"19:34 EDT","volume":5108,"amount":11451.48,"timestamp":1749857675670},"volumeRatio":0.37572268761252897},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NRXS\",,,,,undefined,":{"symbol":"NRXS","floatShares":4721001,"roa":"-220.12%","roe":"-2480.49%","lyrEps":-1.221694,"volumeRatio":0.37572268761252897,"shares":8754300,"dividePrice":0,"high":2.3385,"amplitude":0.03413,"preClose":2.3,"low":2.26,"week52Low":1.33,"pbRate":"78.87","psRate":"6.83","week52High":6.2,"institutionHeld":0,"latestPrice":2.29,"eps":-1.234667,"divideRate":0,"volume":90168,"delay":0,"ttmEps":-1.234667,"open":2.28,"prevYearClose":2.35,"prevWeekClose":2.61,"prevMonthClose":2.73,"prevQuarterClose":2.15,"fiveDayClose":2.61,"twentyDayClose":2.36,"sixtyDayClose":2.29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NRXS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2536645735","title":"NeurAxis Stock Doubles with FDA Clearance for IB-Stim","url":"https://stock-news.laohu8.com/highlight/detail?id=2536645735","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536645735?lang=en_us&edition=fundamental","pubTime":"2025-05-20 22:20","pubTimestamp":1747750800,"startTime":"0","endTime":"0","summary":"Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia.The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago.The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510 clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia.This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"NeurAxis Stock Doubles with FDA Clearance for IB-Stim","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2536324645","title":"Nasdaq Falls 100 Points; Home Depot Sales Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2536324645","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536324645?lang=en_us&edition=fundamental","pubTime":"2025-05-20 22:01","pubTimestamp":1747749663,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45519198/nasdaq-falls-100-points-home-depot-sales-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MULN","NDAQ",".IXIC","HD","BLMZ","SYTA","EKSO","NRXS","PCOM","PTIX"],"gpt_icon":0},{"id":"2536648305","title":"Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2536648305","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536648305?lang=en_us&edition=fundamental","pubTime":"2025-05-20 21:15","pubTimestamp":1747746905,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to higher premarket Tuesday with the Health Care Select Sector SPDR Fund  up 0.3% and the iShares Biotechnology ETF  recently inactive.Novo Nordisk's  weight-loss drug Wegovy is being offered in smaller doses of a compounded version by online weight-loss tool Noom, Reuters reported, citing senior company officials. Shares of Novo Nordisk were over 3% higher pre-bell.NeurAxis  shares surged past 160% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device for treating functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.Zymeworks  shares were up over 1% after the company said new preclinical data on its experimental respiratory inflammation drug ZW1528 has shown positive results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","LU1093756325.SGD","BK4599","IE00BKVL7J92.USD","BK4585","BK4007","BK4532","ZYME","BK4588","BK4082","IE00BZ1G4Q59.USD","LU1093756168.USD","NRXS","LU0154236417.USD","BK4581","BK7104","IBB","NVO.AU","BK4139"],"gpt_icon":1},{"id":"2536201617","title":"NeurAxis Receives FDA Clearance on IB-Stim for Treating Pediatric Dyspepsia; Shares Rise Sharply Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2536201617","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536201617?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:43","pubTimestamp":1747744981,"startTime":"0","endTime":"0","summary":"NeurAxis  shares were up sharply premarket Tuesday after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device for treating functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.The approval is the first FDA-cleared treatment for pediatric functional dyspepsia and builds on the device's prior clearance for irritable bowel syndrome, the company said.NeurAxis said the expanded use nearly doubles IB-Stim's addressable market and will be launched using its existing reimbursement and provider network.IB-Stim is a non-surgical device that uses neuromodulation to treat gut-brain interaction disorders, with no FDA-approved drug therapies currently available for these conditions in children, NeurAxis said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRXS"],"gpt_icon":0},{"id":"2536124226","title":"BRIEF-Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2536124226","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536124226?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:16","pubTimestamp":1747743399,"startTime":"0","endTime":"0","summary":"BRIEF-Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea SymptomsMay 20 (Reuters) - Neuraxis Inc NRXS.A:NEURAXIS AWARDED FIRST","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA6SL0MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2536820612","title":"NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2536820612","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536820612?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742418,"startTime":"0","endTime":"0","summary":"NeurAxis Inc. Secures FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea, Expanding Market Reach. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire  on May 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL5ldbJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS","NDAQ"],"gpt_icon":0},{"id":"2536894612","title":"Neuraxis Awarded First Ever FDA Clearance for the Treatment of Pediatric Fap/Functional Dyspepsia (FD) and Associated Nausea Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2536894612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536894612?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA6SL0MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2536761286","title":"Neuraxis Inc - Commercial Rollout for New Indication Begins Immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2536761286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536761286?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA6SL0MD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2536612896","title":"Neuraxis Inc: Clearance Covers Patients Aged 8-21","url":"https://stock-news.laohu8.com/highlight/detail?id=2536612896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536612896?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA6SL0MD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2535769412","title":"NeurAxis, Inc. Reports Increased Sales Amidst Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2535769412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535769412?lang=en_us&edition=fundamental","pubTime":"2025-05-13 12:20","pubTimestamp":1747110016,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. ( ($NRXS) ) has released its Q1 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors. NeurAxis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-increased-sales-amidst-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-increased-sales-amidst-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS","BK4082"],"gpt_icon":0},{"id":"2534208592","title":"CORRECTION: Neuraxis Q1 EPS $(0.33) Down From $(0.32) YoY, Sales $895.65K Up From $646.63K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2534208592","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534208592?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:43","pubTimestamp":1747053798,"startTime":"0","endTime":"0","summary":"CORRECTION: Neuraxis Q1 EPS $(0.33) Down From $(0.32) YoY, Sales $895.65K Up From $646.63K YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45346038/correction-neuraxis-q1-eps-0-33-down-from-0-32-yoy-sales-895-65k-up-from-646-63k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2534622738","title":"Neuraxis Q1 EPS $(0.33) Misses $(0.24) Estimate, Sales $895.65K Miss $725.00M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534622738","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534622738?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:24","pubTimestamp":1747052668,"startTime":"0","endTime":"0","summary":"Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 3.13 percent decrease over losses of $(0.32) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45345498/neuraxis-q1-eps-0-33-misses-0-24-estimate-sales-895-65k-miss-725-00m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2534222182","title":"Press Release: NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2534222182","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534222182?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:15","pubTimestamp":1747052100,"startTime":"0","endTime":"0","summary":"Conference call will be held today, Monday, May 12 at 9:00 am ET. CARMEL, Ind., May 12, 2025  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.-- Revenues increased 39% year over year to $896 thousand in 1Q25 compared. -- Revenues increased 18% quarter over quarter to $896 thousand in 1Q25. -- Cash balance was $2.0 million as of March 31, 2025.-- Expanded total covered lives to approximately 51 million compared to 4. -- Received a new Current Procedural Terminology  Category I code for. -- to allow for a larger patient population beyond 11-18 years of age. testing and can be used without interrupting clinical workflow. The. Company has just begun the commercialization process and expects the. children's hospitals using NeurAxis' PENFS technology. This level of. evidence puts NeurAxis in a great ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXS"],"gpt_icon":0},{"id":"2533358236","title":"NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533358236","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533358236?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:00","pubTimestamp":1746450000,"startTime":"0","endTime":"0","summary":"Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time. CARMEL, Ind., May 05, 2025  -- NeurAxis, Inc.  , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before market open. The Company has scheduled a conference call for the same day, Monday, May 12, 2025, at 9:00 am ET to review the results.Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future event","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-host-first-quarter-2025-130000371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXS","BK4181","BK4082","HST","BK4588","BK4585","BK4218"],"gpt_icon":0},{"id":"2532502283","title":"The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2532502283","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532502283?lang=en_us&edition=fundamental","pubTime":"2025-05-01 16:49","pubTimestamp":1746089340,"startTime":"0","endTime":"0","summary":"Chicago, IL – May 1, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Johnson & Johnson JNJ, Cisco Systems, Inc. CSCO and NeurAxis, Inc. NRXS.Here are highlights from Wednesday’s Analyst Blog:. Top Stock Reports for Amazon, Johnson & Johnson and Cisco. The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> First Negative GDP in 3+ Years: -0.3%; Pre-Markets ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-amazon-084900432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999015945.SGD","LU1496350502.SGD","LU0080751232.USD","LU0234570918.USD","JNJ","LU0345770308.USD","LU0823421333.USD","LU2111349929.HKD","USAW.SI","LU2381873111.SGD","LU2097829019.USD","BK4585","BK4543","IE000YTNTUN2.SGD","IE00B3S45H60.SGD","LU0109392836.USD","LU0965509010.AUD","CSCO","LU2112291526.USD","LU0234572021.USD","LU2420271590.USD","LU1064131342.USD","LU1935042215.USD","BK4548","IE000ITXATA3.USD","LU1585245621.USD","LU0683600562.USD","LU0820562030.AUD","LU0942090050.USD","BK4020","AMZN","LU2065171402.SGD","LU2065171311.SGD","LU0203345920.USD","LU0823421416.USD","IE00BYQQ9H92.USD","IE00B19Z3581.USD","LU1496350171.SGD","IE00BWXC8680.SGD","IE00B1BXHZ80.USD","LU1232071149.USD","LU1839511570.USD","LU1551013342.USD","LU2602419157.SGD","NRXS","LU1069344957.HKD","LU0786609619.USD","BK4554","LU0203347892.USD","LU2125154778.USD"],"gpt_icon":1},{"id":"2527414931","title":"NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527414931","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527414931?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:00","pubTimestamp":1744722000,"startTime":"0","endTime":"0","summary":"To access the live presentation, please use the following information:. If you would like to book 1x1 investor meetings with NeurAxis, and plan to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please make sure you are registered here: REGISTER. The Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub website is available here: HOME PAGE. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-present-planet-microcap-showcase-130000251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2522708411","title":"NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708411","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708411?lang=en_us&edition=fundamental","pubTime":"2025-03-24 23:20","pubTimestamp":1742829600,"startTime":"0","endTime":"0","summary":"Shares of NeurAxis, Inc. NRXS have gained 0.9% since the company reported earnings for the quarter ended Dec. 31, 2024. This compares favorably to the S&P 500 Index, which declined 0.1% over the same time frame. Over the past month, NeurAxis stock has climbed 3.2%, while the S&P 500 saw a 5% decline.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.NeurAxis reported fourth-quarter 2024 revenues of $761 thousand, a 43% increase from $531 thousand a year earlier. This robust growth was primarily driven by a 45% increase in unit sales, reflecting stronger adoption of the company's IB-Stim therapy through both insurance-covered treatments and the company’s financial assistance program. For the full year, revenues rose 9.2% to $2.7 million from $2.5 million in 2023.CFO Tim Henrichs added that revenue growth in first-quarter 2025 has continued the momentum seen in the third and fourth quarters of 2024. He reiterated that NRXS is targeting c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuraxis-stock-gains-post-q4-152000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["POST","NRXS"],"gpt_icon":0},{"id":"2521264903","title":"NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2521264903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521264903?lang=en_us&edition=fundamental","pubTime":"2025-03-22 08:29","pubTimestamp":1742603350,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. (($NRXS)) has held its Q4 earnings call. Read on for the main highlights of the call. NeurAxis, Inc. recently held its fourth quarte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2521442264","title":"NeurAxis, Inc. Reports Strong Q4 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521442264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521442264?lang=en_us&edition=fundamental","pubTime":"2025-03-21 12:07","pubTimestamp":1742530068,"startTime":"0","endTime":"0","summary":"NeurAxis, Inc. ( ($NRXS) ) has released its Q4 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors. NeurAxis...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-2024-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuraxis-inc-reports-strong-q4-2024-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","NRXS"],"gpt_icon":0},{"id":"2520455412","title":"Neuraxis reports Q4 revenue $761,000 vs. $531,000 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520455412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520455412?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:20","pubTimestamp":1742473219,"startTime":"0","endTime":"0","summary":"Brian Carrico, CEO commented, “Our strong performance in 4Q24 capped off a transformational year, as we significantly expanded insurance coverage f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuraxis-reports-q4-revenue-761000-vs-531000-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuraxis-reports-q4-revenue-761000-vs-531000-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXS"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NRXS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"NRXS","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.31},{"market":"US","date":"2024-11-12","symbol":"NRXS","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2024-05-22","symbol":"NRXS","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1716350400000,"reportTimeType":"pre","actualEps":-1.18},{"date":"2024-04-09","symbol":"NRXS","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1712649600000,"name":null,"time":"","dateTimestamp":1712635200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NRXS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NRXS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1743480000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NRXS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NRXS","date":"2025-06-13","current":-2.39715,"percent":0.266958,"low":-5.858297,"twenty":-2.741059,"median":-1.797378,"eighty":-1.363902,"high":-1.102985,"avg":-2.052745,"sd":0.914207,"marketCap":20134947},"quantilePoints":[{"date":"2023-08-11","current":-5.782091,"twenty":-5.768755,"median":-5.748751,"eighty":-5.728747,"marketCap":37088246},{"date":"2023-08-18","current":-4.307523,"twenty":-5.768755,"median":-4.8581,"eighty":-4.540163,"marketCap":27629878},{"date":"2023-08-25","current":-5.169028,"twenty":-5.751022,"median":-5.049374,"eighty":-4.792871,"marketCap":33155854},{"date":"2023-09-01","current":-4.077788,"twenty":-5.737773,"median":-4.8581,"eighty":-4.51237,"marketCap":26156284},{"date":"2023-09-08","current":-3.972493,"twenty":-5.715411,"median":-4.776564,"eighty":-4.163939,"marketCap":25480887},{"date":"2023-09-15","current":-4.2118,"twenty":-5.169028,"median":-4.537257,"eighty":-4.135222,"marketCap":27015881},{"date":"2023-09-22","current":-3.404102,"twenty":-4.977582,"median":-4.460679,"eighty":-3.924632,"marketCap":22134602},{"date":"2023-09-29","current":-3.117972,"twenty":-4.939293,"median":-4.259661,"eighty":-3.570458,"marketCap":20274090},{"date":"2023-10-06","current":-2.780894,"twenty":-4.929721,"median":-4.135222,"eighty":-3.187686,"marketCap":18082296},{"date":"2023-10-13","current":-2.635338,"twenty":-4.8581,"median":-3.948562,"eighty":-2.796216,"marketCap":17135840},{"date":"2023-10-20","current":-2.175686,"twenty":-4.8581,"median":-3.848054,"eighty":-2.757911,"marketCap":14147031},{"date":"2023-10-27","current":-1.509267,"twenty":-4.825486,"median":-3.752331,"eighty":-2.702799,"marketCap":9813755},{"date":"2023-11-03","current":-1.716034,"twenty":-4.68467,"median":-3.48728,"eighty":-2.543407,"marketCap":11158221},{"date":"2023-11-10","current":-1.930538,"twenty":-4.539172,"median":-3.202242,"eighty":-2.224746,"marketCap":12552999},{"date":"2023-11-17","current":-1.957351,"twenty":-4.520027,"median":-3.117972,"eighty":-1.955053,"marketCap":12727346},{"date":"2023-11-24","current":-1.701354,"twenty":-4.498969,"median":-2.853673,"eighty":-1.872315,"marketCap":15868542},{"date":"2023-12-01","current":-1.792093,"twenty":-4.460679,"median":-2.773233,"eighty":-1.820222,"marketCap":16714864},{"date":"2023-12-08","current":-1.587931,"twenty":-4.430048,"median":-2.74642,"eighty":-1.743503,"marketCap":14810639},{"date":"2023-12-15","current":-1.310043,"twenty":-4.288378,"median":-2.635338,"eighty":-1.702488,"marketCap":12218777},{"date":"2023-12-22","current":-1.293029,"twenty":-4.202228,"median":-2.547238,"eighty":-1.613439,"marketCap":12060091},{"date":"2023-12-29","current":-1.446151,"twenty":-4.173511,"median":-2.497442,"eighty":-1.588385,"marketCap":13488260},{"date":"2024-01-05","current":-1.429138,"twenty":-4.152452,"median":-2.378737,"eighty":-1.584528,"marketCap":13329575},{"date":"2024-01-12","current":-1.392275,"twenty":-4.112248,"median":-2.175686,"eighty":-1.511242,"marketCap":12985756},{"date":"2024-01-19","current":-1.355412,"twenty":-4.056729,"median":-1.957351,"eighty":-1.45629,"marketCap":12641938},{"date":"2024-01-26","current":-1.239153,"twenty":-3.962921,"median":-1.922877,"eighty":-1.429138,"marketCap":11557588},{"date":"2024-02-02","current":-1.372482,"twenty":-3.924632,"median":-1.854476,"eighty":-1.392842,"marketCap":12801152},{"date":"2024-02-09","current":-1.378097,"twenty":-3.909316,"median":-1.843707,"eighty":-1.378097,"marketCap":12853519},{"date":"2024-02-16","current":-2.129528,"twenty":-3.828909,"median":-1.838608,"eighty":-1.378199,"marketCap":19862125},{"date":"2024-02-23","current":-1.820449,"twenty":-3.752331,"median":-1.838608,"eighty":-1.378607,"marketCap":16979339},{"date":"2024-03-01","current":-1.978732,"twenty":-3.675753,"median":-1.854202,"eighty":-1.389439,"marketCap":18455643},{"date":"2024-03-08","current":-1.916859,"twenty":-3.570458,"median":-1.915216,"eighty":-1.392275,"marketCap":17878557},{"date":"2024-03-15","current":-1.848805,"twenty":-3.404102,"median":-1.916859,"eighty":-1.39511,"marketCap":17243815},{"date":"2024-03-22","current":-1.838597,"twenty":-3.323839,"median":-1.916859,"eighty":-1.417795,"marketCap":17148604},{"date":"2024-03-28","current":-1.894174,"twenty":-3.226561,"median":-1.916859,"eighty":-1.417795,"marketCap":17666976},{"date":"2024-04-05","current":-1.758066,"twenty":-3.190597,"median":-1.910366,"eighty":-1.422332,"marketCap":16397493},{"date":"2024-04-12","current":-1.142765,"twenty":-3.131915,"median":-1.86159,"eighty":-1.413258,"marketCap":16714864},{"date":"2024-04-19","current":-1.465319,"twenty":-3.117972,"median":-1.854476,"eighty":-1.387273,"marketCap":21432755},{"date":"2024-04-26","current":-1.352644,"twenty":-2.952498,"median":-1.848805,"eighty":-1.378097,"marketCap":19784691},{"date":"2024-05-03","current":-1.487863,"twenty":-2.819199,"median":-1.840871,"eighty":-1.378505,"marketCap":21762500},{"date":"2024-05-10","current":-1.429294,"twenty":-2.783958,"median":-1.837463,"eighty":-1.386693,"marketCap":20905823},{"date":"2024-05-17","current":-1.393223,"twenty":-2.774765,"median":-1.818037,"eighty":-1.378097,"marketCap":20378231},{"date":"2024-05-24","current":-1.371116,"twenty":-2.767104,"median":-1.803436,"eighty":-1.371029,"marketCap":19982537},{"date":"2024-05-31","current":-1.47794,"twenty":-2.760975,"median":-1.792093,"eighty":-1.371936,"marketCap":21539390},{"date":"2024-06-07","current":-1.363902,"twenty":-2.744122,"median":-1.763737,"eighty":-1.370941,"marketCap":19877400},{"date":"2024-06-14","current":-1.354779,"twenty":-2.702799,"median":-1.731355,"eighty":-1.363795,"marketCap":19744441},{"date":"2024-06-21","current":-1.176878,"twenty":-2.662963,"median":-1.716034,"eighty":-1.356108,"marketCap":17151736},{"date":"2024-06-28","current":-1.268109,"twenty":-2.632274,"median":-1.701354,"eighty":-1.353498,"marketCap":18481328},{"date":"2024-07-05","current":-1.277232,"twenty":-2.61542,"median":-1.666559,"eighty":-1.34512,"marketCap":18614288},{"date":"2024-07-12","current":-1.341094,"twenty":-2.558729,"median":-1.590766,"eighty":-1.332883,"marketCap":19545002},{"date":"2024-07-19","current":-1.35934,"twenty":-2.521956,"median":-1.587931,"eighty":-1.323502,"marketCap":19810920},{"date":"2024-07-26","current":-1.455133,"twenty":-2.489781,"median":-1.573733,"eighty":-1.332883,"marketCap":21206992},{"date":"2024-08-02","current":-1.450571,"twenty":-2.426978,"median":-1.525548,"eighty":-1.336905,"marketCap":21140512},{"date":"2024-08-09","current":-1.394691,"twenty":-2.273806,"median":-1.496186,"eighty":-1.323502,"marketCap":21277441},{"date":"2024-08-16","current":-1.426083,"twenty":-2.175686,"median":-1.482902,"eighty":-1.332883,"marketCap":21756354},{"date":"2024-08-23","current":-1.381238,"twenty":-2.171547,"median":-1.47794,"eighty":-1.336905,"marketCap":21072192},{"date":"2024-08-30","current":-1.371551,"twenty":-2.149899,"median":-1.473379,"eighty":-1.338938,"marketCap":20924413},{"date":"2024-09-06","current":-1.322939,"twenty":-2.129528,"median":-1.468827,"eighty":-1.338399,"marketCap":20182781},{"date":"2024-09-13","current":-1.331908,"twenty":-2.099077,"median":-1.465364,"eighty":-1.338399,"marketCap":20319614},{"date":"2024-09-20","current":-1.16598,"twenty":-2.098394,"median":-1.460855,"eighty":-1.331971,"marketCap":17788214},{"date":"2024-09-27","current":-1.421599,"twenty":-2.098337,"median":-1.455564,"eighty":-1.331908,"marketCap":21687938},{"date":"2024-10-04","current":-1.309485,"twenty":-2.069981,"median":-1.449539,"eighty":-1.331908,"marketCap":19977533},{"date":"2024-10-11","current":-1.255671,"twenty":-2.035954,"median":-1.446151,"eighty":-1.322939,"marketCap":19156538},{"date":"2024-10-18","current":-1.797639,"twenty":-2.024612,"median":-1.444415,"eighty":-1.321385,"marketCap":27424822},{"date":"2024-10-25","current":-1.755972,"twenty":-1.996256,"median":-1.447329,"eighty":-1.322939,"marketCap":26789147},{"date":"2024-11-01","current":-1.541743,"twenty":-1.990585,"median":-1.452852,"eighty":-1.322939,"marketCap":23520871},{"date":"2024-11-08","current":-1.428587,"twenty":-1.990585,"median":-1.455564,"eighty":-1.331908,"marketCap":21794560},{"date":"2024-11-15","current":-3.411128,"twenty":-2.024612,"median":-1.460855,"eighty":-1.331971,"marketCap":28605361},{"date":"2024-11-22","current":-3.302839,"twenty":-2.098394,"median":-1.465364,"eighty":-1.336392,"marketCap":27697254},{"date":"2024-11-29","current":-3.219347,"twenty":-2.159131,"median":-1.468817,"eighty":-1.336504,"marketCap":26997104},{"date":"2024-12-06","current":-2.912995,"twenty":-2.466799,"median":-1.473379,"eighty":-1.338026,"marketCap":24428070},{"date":"2024-12-13","current":-2.685587,"twenty":-2.629209,"median":-1.47794,"eighty":-1.340555,"marketCap":22521046},{"date":"2024-12-20","current":-2.598955,"twenty":-2.667419,"median":-1.482902,"eighty":-1.343391,"marketCap":21794560},{"date":"2024-12-27","current":-2.631442,"twenty":-2.646774,"median":-1.48801,"eighty":-1.344803,"marketCap":22066992},{"date":"2025-01-03","current":-2.620613,"twenty":-2.63378,"median":-1.492149,"eighty":-1.345361,"marketCap":21976182},{"date":"2025-01-10","current":-2.696416,"twenty":-2.684745,"median":-1.511736,"eighty":-1.345361,"marketCap":22611856},{"date":"2025-01-17","current":-3.086259,"twenty":-2.726737,"median":-1.541684,"eighty":-1.345361,"marketCap":25881040},{"date":"2025-01-24","current":-3.378208,"twenty":-2.750561,"median":-1.553589,"eighty":-1.345361,"marketCap":28329296},{"date":"2025-01-31","current":-2.707245,"twenty":-2.772219,"median":-1.569613,"eighty":-1.345361,"marketCap":22702667},{"date":"2025-02-07","current":-2.177934,"twenty":-2.772219,"median":-1.58226,"eighty":-1.345361,"marketCap":18263920},{"date":"2025-02-14","current":-2.066684,"twenty":-2.765572,"median":-1.588214,"eighty":-1.347936,"marketCap":17330989},{"date":"2025-02-21","current":-1.976828,"twenty":-2.759443,"median":-1.595987,"eighty":-1.34938,"marketCap":16577467},{"date":"2025-02-28","current":-1.865578,"twenty":-2.752031,"median":-1.631764,"eighty":-1.352063,"marketCap":15644536},{"date":"2025-03-07","current":-1.874135,"twenty":-2.746229,"median":-1.701354,"eighty":-1.352644,"marketCap":15716300},{"date":"2025-03-14","current":-1.848462,"twenty":-2.736972,"median":-1.707025,"eighty":-1.353993,"marketCap":15501008},{"date":"2025-03-21","current":-2.022525,"twenty":-2.730108,"median":-1.721122,"eighty":-1.354689,"marketCap":16668645},{"date":"2025-03-28","current":-1.839535,"twenty":-2.72024,"median":-1.731355,"eighty":-1.355285,"marketCap":15160530},{"date":"2025-04-04","current":-1.619771,"twenty":-2.709411,"median":-1.734735,"eighty":-1.355412,"marketCap":13349348},{"date":"2025-04-11","current":-1.567238,"twenty":-2.698582,"median":-1.72621,"eighty":-1.355412,"marketCap":12916396},{"date":"2025-04-17","current":-1.400883,"twenty":-2.696416,"median":-1.714305,"eighty":-1.356456,"marketCap":11545382},{"date":"2025-04-25","current":-2.136347,"twenty":-2.689919,"median":-1.71517,"eighty":-1.35815,"marketCap":17606708},{"date":"2025-05-02","current":-2.031281,"twenty":-2.685587,"median":-1.72971,"eighty":-1.35913,"marketCap":16740804},{"date":"2025-05-09","current":-1.751104,"twenty":-2.683062,"median":-1.74461,"eighty":-1.35934,"marketCap":14431728},{"date":"2025-05-16","current":-1.932928,"twenty":-2.670909,"median":-1.755972,"eighty":-1.361715,"marketCap":16235694},{"date":"2025-05-23","current":-3.157985,"twenty":-2.689919,"median":-1.7649,"eighty":-1.363299,"marketCap":26525604},{"date":"2025-05-30","current":-2.980805,"twenty":-2.713742,"median":-1.78075,"eighty":-1.363433,"marketCap":25037369},{"date":"2025-06-06","current":-2.709822,"twenty":-2.741059,"median":-1.794882,"eighty":-1.363742,"marketCap":22761245},{"date":"2025-06-13","current":-2.39715,"twenty":-2.741059,"median":-1.797378,"eighty":-1.363902,"marketCap":20134947}],"updateTime":1749944503072}}}